Tempest Therapeutics enters USD 50 million equity purchase deal with Lincoln Park Capital Fund - TPST News | RalliesTempest Therapeutics enters USD 50 million equity purchase deal with Lincoln Park Capital Fund
T
TPST• Tempest Therapeutics signs equity line with Lincoln Park Capital
- Tempest Therapeutics set a $50 million equity line with Lincoln Park Capital to sell common stock in unregistered transactions.
- Initial availability is $25 million, with a further $25 million increase later, subject to conditions.
- Sales can run up to 24 months once a resale registration statement becomes effective; filing due within 10 days of signing.
- Commitment fee paid in stock: 560,356 shares issued at signing, with 350,223 more shares due after full draw of $25 million.
- Issuances capped at 19.99% without shareholder approval unless average sale price meets $1.39; Lincoln Park ownership capped at 4.99%.
•
